Background: The degree of platelet inhibition (PI) induced by GPIth/llla antagonists has been shown to influence clinical outcomes following percutaneous coronary intervention (PCI). There is no comparative data on the degree of PI using different commercially available point-of-care PI assays. Methods: We prospectively enrolled 24 pts (66 ± 10 yrs, 18 males) who received a GPifb/llla inhibitor during PCI. Pts received tirofiban; n=15 (10mcg/kg, 0.15mcg/kg/min), eptifibitide; n=7 (single bolus; 180mcg/kg, 2mcg/kg/min), and abciximab; n=2 (0.25mg/ kg, 0.125mcg/kg/min). We compared the degree of PI using 3 different assays: 1) 20p.mol ADP/citrate in the IchorTM piatelet analyzer (Helena Laboratories, Beaumont, TX), 2) iso-TRAP/citrate and 3) iso-TRAP/PPACK as piatelet agonists/enticoaguiants respectively in the UltagraTM system (Accumetrics, San-Diego, CA). PI was measured in all pts 30 min following GPIIb/llia bolus, with each assay performed on the same blood sample. Results: The mean ± SD values of PI following GPIIb/Itia administration are shown below. Conclusion: There is significant variation in the degree of PI assessed by the three assays. The greater inter-patient variability and the lower mean PI, detected by the IchorTM system may enhance patient stratification based upon response to GPIIb/llla inhibitors. The practical implications of these findings need to be validated in large-scale clinical outcome trials. Background: Few data exist to assess the significance of troponin following stent percutanecus coronary intervention (PCI). We examined the predictive utility of post-PCI troponin for subsequent cardiac events in the ESPRIT trial. Methods: Troponin was measured in local laboratories at the discretion of the site investigator. Of participants that had a post-PCI troponin (n=392), 52 were excluded due to an endpoint of death or MI (core CK-MB 3X upper limit of normal (ULN)) at 48 hours. In the remaining population (n--341), we assessed the relation of troponin elevation to occurrence of the ESPRIT-defined composite of death, MI, and TVR to 365 days in a Cox proportional-hazards (PH) model. We dichotomized (<=ULN or >ULN) troponin and included it as a time-dependent covadate. Results: The baseline characteristics were similar in the overall tdal population (n=2064), participants with post-procedure troponin measured (n=341), and participants with an elevated (n=123) or normal (n=218) tmponin. An elevated post-PCI troponin was associated with a 3-fold higher risk for subsequent cardiac events (HR-.-.-~.97;p=0.019). These results did not differ significantly with troponin >3X ULN in the time to event model. Conclusion: In a low-risk patient population undergoing elective PCI, an elevated post-PCI troponin >ULN was associated with a significant increase in subsequent cardiac events. Development of strategies to prevent even minor myocardial necrosis as detected by troponin post-PCI is warranted. Background: Baseline plateiat activation correlates with the need for target vessel revascularo ization (TVR) following PCI but is of limited clinical ~lity due to the need for specialized testing. The Ultegra-RPFA is a simple, point-of-care assay approved for use in monitoring plateiet function in patients treated with GPIIb/llia antagonists that also quantifies the patient's baseline platelet function. Method: As part of the GOLD study, baseline Platslet Activation Units (PAU) were measured using the Uitegra-RPFA in 500 patients undergoing a pemutanecus coronary intervention with the adjunctive use of a GPIII:YlIla antagonist. TVR at 7 months was evaluated in a subset of 194 abciximab-treatad patients and analyzed with respect to baseline platelet function. Results: Baseline plateiet function ranged from 52 to 471 PAU (median 234). Patients with the lowest PAU values at baseline, consistent with more activated or "exhausted" platelets had a significantly greater risk of TVR than those paitents with highest baseline PAU levels (Figure) . Conclusion: These results confirm that increased levels of plateiet a~vation prior to PCI are assooated with an increased risk of TVR, and confirm that this can now be easily determined utilizing a simple point.of-care assay. Routine platelet function monitoring may help to opti° mize the future use of more expensive therapies designed to prevent restenosis. 
887-1 Elevated Troponin Following Percutaneous Coronary Intervention Predicts Subsequent Events: Results

